ArticlePlant biotechnology journal2023
CRISPR/Cas9-mediated seamless gene replacement in protoplasts expands the resistance spectrum to TMV-U1 strain in regenerated Nicotiana tabacum.
Article in Plant biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Tobamoviruses: Advances in Molecular Biology, Host Interactions and Integrated Disease Management.Biology · 2026Review
- A dual-platform toolkit for transient gene expression and genome editing in rubber dandelion (aBIOTECH · 2026Article
- Establishment of a protoplast isolation and transient transformation system for tung tree (Vernicia fordii).Plant methods · 2026Article
- Protoplast-Based Functional Genomics and Genome Editing: Progress, Challenges and Applications.Plant, cell & environment · 2026Review
- The evolving landscape of precise DNA insertion in plants.Nature communications · 2025Review
- Nanotechnology Strategies in Plant Genetic Engineering: Intelligent Delivery and Precision Editing.Plants (Basel, Switzerland) · 2025Review
- Identification of a gene conferring broad-spectrum orthotospovirus resistance in Solanaceae.Science advances · 2025Article
- The Emerging Applications of Artificial MicroRNA-Mediated Gene Silencing in Plant Biotechnology.Non-coding RNA · 2025Review
- Genetic engineering, including genome editing, for enhancing broad-spectrum disease resistance in crops.Plant communications · 2025Review
- Establishment and application of Agrobacterium-delivered CRISPR/Cas9 system for wild tobacco (Frontiers in plant science · 2024Article
- Comparative transcriptome analysis reveals nicotine metabolism is a critical component for enhancing stress response intensity of innate immunity system in tobacco.Frontiers in plant science · 2024Article
- Genetic breakthroughs in theFrontiers in plant science · 2023Review
Corrections and comments
- Erratum issuedCorrection.2024
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
CRISPR/Cas-based genome editing is now extensively used in plant breeding and continues to evolve. Most CRISPR/Cas current applications in plants focus on gene knock-outs; however, there is a pressing need for new methods to achieve more efficient delivery of CRISPR components and gene knock-ins to improve agronomic traits of crop cultivars. We report here a genome editing system that combines the advantages of protoplast technologies with recent CRISPR/Cas advances to achieve seamless large fragment insertions in the model Solanaceae plant Nicotiana tabacum. With this system, two resistance-related regions of the N' gene were replaced with homologous fragments from the N'alata gene to confer TMV-U1 resistance in the T0 generation of GMO-free plants. Our study establishes a reliable genome-editing tool for efficient gene modifications and provides a detailed description of the optimization process to assist other researchers adapt this system for their needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.